Tamoxifen Breast Cancer Prevention Trial--an update.
Ford
L G
LG
Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, MD 20892, USA.
Johnson
K A
KA
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D017024:Chemotherapy, Adjuvant; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010919:Placebos; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000139:chemically induced / Q000453:epidemiology
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D010919:Placebos; D013629:Tamoxifen